By IDSE News Staff
The FDA granted a new indication for the adjuvanted zoster vaccine recombinant (RZV; Shingrix, GlaxoSmithKline) to prevent herpes zoster in adults ages 18 years and older who are or who will be at increased risk for shingles due to immunodeficiency or immunosuppression caused by disease or therapy.
These individuals have a greater risk for shingles and associated complications than immunocompetent individuals.
RZV, a recombinant subunit adjuvanted vaccine, given intramuscularly